Episode Summary
Dr. Greg Katz, preventive cardiologist at NYU Langone and co-host of Beyond Journal Club, joins Anish to dissect the online cholesterol debate — specifically the claims made by science communicator Nick Norwitz, who has maintained an LDL over 500 mg/dL on a low-carb diet for seven years with no coronary plaque on CTA. Katz takes the data point seriously, walks through the limitations of coronary CTA and the flawed Keto CTA study, and explains why he still believes the burden of proof lies with those arguing diet-induced hypercholesterolemia is safe — while acknowledging where the cardiology establishment, including the new lipid guidelines, overcorrects. The conversation covers the accountability gap between clinicians and content creators, the failure of risk calculators in young patients, and what a well-designed trial to actually answer this question would look like.
Chapter Markers
00:00 Introduction — Dr. Greg Katz, NYU Langone cardiologist and Beyond Journal Club co-host
01:40 What prompted the Substack: patients bringing in Nick Norwitz's content
02:51 Who is Nick Norwitz — LDL of 500, low-carb diet, and the clean CTA
05:38 Why Katz takes the question seriously but disagrees with the framing
08:01 Familial hypercholesterolemia outliers: why some FH patients never have events
10:05 The 50/50 problem — half of high-cholesterol patients have heart disease, half don't
12:27 The Jody Plute story: homozygous FH, Thomas Starzl, and the portacaval shunt experiments
17:37 Seven years of LDL 500 — is that long enough to know anything?
18:21 Limitations of coronary CTA: what it can and can't see
21:00 Why LDL gets put on a pedestal — and the cognitive dissonance of a diet that works
22:05 The conflict of interest argument — and why it cuts both ways
25:43 Burden of proof: mechanisms vs. outcomes data
27:16 Statins and GLP-1 levels — why a mechanistic claim isn't the same as a clinical outcome
31:38 Physician accountability vs. content creator accountability
35:24 The Keto CTA study: what it found, what it didn't, and why the blinding controversy matters
44:40 The new lipid guidelines: where they overcomplicate, where they overprescribe
49:38 GLP-1 deficiency framing and the over-medicalization of well people
55:54 Longevity medicine as "over-medicalization of well people"
57:35 What a well-designed trial would actually look like
1:00:01 Why the debate needs real research, not conjecture
1:02:37 How Katz talks to statin-hesitant patients in clinic
1:07:06 Wrap
Co-Host Handles
@anish_koka and @drdigiorgio
Show Handle
@drsloungepod
Subscribe Links
Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR
Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658
YouTube: https://www.youtube.com/@TheDoctorsLoungePod
